Researcher
Patrick Neven
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Jan 2012 → Today
Projects
1 - 10 of 13
- Early folliculogenesis and ovarian aging in women with genetic predisposition to (breast)cancerFrom15 Jul 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Effectiveness of an eHealth self-management support program for persistent pain after breast cancer treatmentFrom1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- breastcancer and sexualityFrom25 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical, pathological and molecular characterization of invasive lobular carcinoma (ILC)From12 Aug 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Epidemiological study of relapse in breast, ovarian and cervical cancers.From1 Oct 2018 → 30 Sep 2021Funding: Nonprofit institution or equivalents
- Towards a better selection of systemic treatment for patients with ER-positive HER2-negative breast cancer: the use of prognostic and predictive markers in early and metastatic settingFrom1 May 2017 → 14 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Role of combined chemo- and immunotherapy in early breast cancerFrom1 Oct 2016 → 30 Sep 2020Funding: Nonprofit institution or equivalents
- Key biological processes involved in breast cancer invasion and metastases leading to residual disease after local therapy of breast tumors.From1 Jul 2014 → 30 Jun 2018Funding: Private funding of national origin - undefined
- Assessment of market access policies and instruments for oncology drugs.From1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
Publications
21 - 30 of 572
- Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival(2023)
Authors: Diether Lambrechts, Ines Nevelsteen, Patrick Neven, Hans Wildiers
Pages: 16142 - 16162 - Obesity-associated changes in molecular biology of primary breast cancer(2023)
Authors: Ha Linh Nguyen, Tatjana Geukens, Maxim De Schepper, Stefan Naulaerts, Ines Nevelsteen, Patrick Neven, Karen Van Baelen, Hanne Vos, Hans Wildiers, Beppe Floris, et al.
- Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences(2023)
Authors: Patrick Neven
- PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial(2023)
Authors: Liselore Loverix, Ignace Vergote, Pieter Busschaert, Tom Venken, Bram Boeckx, Hilde Brems, Els Van Nieuwenhuysen, Thaïs Baert, Sileny Han, Patrick Neven, et al.
Pages: 131 - 139 - Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer(2023)
Authors: Tatjana Geukens, Maxim De Schepper, François Richard, Karen Van Baelen, Ha Linh Nguyen, Sophia Leduc, Anirudh Pabba, Gitte Zels, Ann Smeets, Ines Nevelsteen, et al.
Pages: 152 - 160 - XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease(2023)
Authors: Patrick Neven
- Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial(2023)
Authors: Patrick Neven
- Relation between circulating biomarkers at diagnosis of early luminal-like breast cancer and subsequent risk of distant metastases.(2023)
Authors: Yentl Lambrechts, Beppe Floris, Patrick Neven, Ines Nevelsteen, François Richard, Christine Desmedt, Hans Wildiers, Sigrid Hatse
- The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study(2023)
Authors: Patrick Neven, Beppe Floris, Eva Oldenburger, Sileny Han, Chantal Van Ongeval, Ann Smeets, Hans Wildiers, Nele Laudus, Els Dequeker
Pages: E273 - E280 - Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET)(2023)
Authors: Patrick Neven